Oxaliplatin Injection Clinical Trials

• Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00355888 - Recruiting
  Cancer
  
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
  ClinicalTrials.gov Identifier: NCT00091182 - Active, not recruiting
  Cancer
  
• Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00275119 - Active, not recruiting
  Pancreatic Cancer
  
• Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
  ClinicalTrials.gov Identifier: NCT00387387 - Recruiting
  Colorectal Cancer
  
• TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00057720 - Active, not recruiting
  Ovarian Neoplasms
  
• A 2x2 (4-way) study of capecitabine in combo w/ oxaliplatin (XELOX) w/ or w/out bevacizumab vs. fluorouracil/leucovorin w/ oxaliplatin (FOLFOX-4) w/ or w/out bevacizumab as first-line treatment for pts w/ metastatic colorectal cancer
  ClinicalTrials.gov Identifier: NCT00069095 - Active, not recruiting
  Metastatic Colorectal Cancer
  
• Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Metastatic or Inoperable Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (Cancer)
  ClinicalTrials.gov Identifier: NCT00084617 - Active, not recruiting
  Esophageal Cancer; Gastric Cancer
  
• Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00070213 - Recruiting
  Colon Cancer; Quality of Life; Rectal Cancer
  
• Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
  ClinicalTrials.gov Identifier: NCT00004173 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
  ClinicalTrials.gov Identifier: NCT00040859 - Active, not recruiting
  Esophageal Cancer; Gastric Cancer
  
• Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00086983 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00004206 - Active, not recruiting
  recurrent ovarian epithelial cancer
  
• Gemcitabine, Oxaliplatin in Combination with Bevacizumab in Patients with Hepatocellular Carcinoma
  ClinicalTrials.gov Identifier: NCT00142467 - Active, not recruiting
  Hepatocellular Carcinoma
  
• Phase III Study of Cetuximab, Oxaliplatin, 5-FU/LV vs. Oxaliplatin, 5-FU/LV in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00061815 - Active, not recruiting
  Colorectal Cancer
  
• Oxaliplatin and Capecitabine Versus Follow-Up After Resection of Colorectal Liver Metastases
  ClinicalTrials.gov Identifier: NCT00156975 - Active, not recruiting
  Colorectal Neoplasms; Liver Metastases
  
• Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
  ClinicalTrials.gov Identifier: NCT00074321 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084643 - Active, not recruiting
  adult solid tumor; Colon Cancer; Rectal Cancer
  
• A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00504192 - Recruiting
  Advanced Biliary Tract Adenocarcinoma; Gemcitabine; Oxaliplatin; Combination Chemotherapy; Efficacy
  
• Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients with Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00159432 - Recruiting
  Colorectal Cancer
  
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00096070 - Active, not recruiting
  adenocarcinoma of the pancreas; stage II pancreatic cancer; stage III pancreatic cancer
  
• Penile Injection Anxiety
  ClinicalTrials.gov Identifier: NCT00582231 - Recruiting
  Penile Injection Therapy; Erectile Dysfunction; Radical Pelvic Surgery
  
• CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
  ClinicalTrials.gov Identifier: NCT00174616 - Active, not recruiting
  Rectal Neoplasms
  
• Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
  ClinicalTrials.gov Identifier: NCT00006121 - Active, not recruiting
  stage III breast cancer; stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00006117 - Active, not recruiting
  stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00087802 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater
  ClinicalTrials.gov Identifier: NCT00354887 - Active, not recruiting
  Gastrointestinal Cancer
  
• Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00374660 - Active, not recruiting
  Liver Cancer
  
• Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
  ClinicalTrials.gov Identifier: NCT00452374 - Active, not recruiting
  Leukemia
  
• Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00104689 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum
  
• Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00101075 - Active, not recruiting
  high-grade salivary gland carcinoma; low-grade salivary gland carcinoma; Salivary Gland Cancer
  
• Safety of KAI-9803 for Injection with Angioplasty following Heart Attack
  ClinicalTrials.gov Identifier: NCT00093197 - Active, not recruiting
  Myocardial Infarction
  
• Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00080951 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum
  
• Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
  ClinicalTrials.gov Identifier: NCT00006391 - Active, not recruiting
  recurrent ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer
  
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
  ClinicalTrials.gov Identifier: NCT00003427 - Active, not recruiting
  Pancreatic Cancer; Colon Cancer; Gastric Cancer; Rectal Cancer; Esophageal Cancer; Colorectal Cancer; adult primary liver cancer
  
• Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
  ClinicalTrials.gov Identifier: NCT00250822 - Active, not recruiting
  Liver Cancer
  
• A Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in Patients With Stage 5 Chronic Kidney Disease
  ClinicalTrials.gov Identifier: NCT00257920 - Recruiting
  Stage 5 Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism
  
• Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
  ClinicalTrials.gov Identifier: NCT00096278 - Active, not recruiting
  adenocarcinoma of the colon; stage II colon cancer; stage III colon cancer
  
• Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00017082 - Active, not recruiting
  recurrent colon cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer
  
• Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00012389 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer
  
• Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
  ClinicalTrials.gov Identifier: NCT00004931 - Active, not recruiting
  stage III colon cancer; stage II colon cancer
  
• Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00112528 - Active, not recruiting
  duct cell adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
  
• Flavopiridol, Oxaliplatin, Fluorouracil, and Leucovorin in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00080990 - Recruiting
  unspecified adult solid tumor, protocol specific
  
• Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer.
  ClinicalTrials.gov Identifier: NCT00177307 - Active, not recruiting
  Cancer
  
• Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00087334 - Active, not recruiting
  recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; Stage IV rectal cancer
  
• Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00242190 - Active, not recruiting
  Pancreatic Neoplasms
  
• Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
  ClinicalTrials.gov Identifier: NCT00436800 - Active, not recruiting
  Nasopharyngeal Neoplasms
  
• Oxaliplatin in Treating Patients With Liver Cancer
  ClinicalTrials.gov Identifier: NCT00052364 - Active, not recruiting
  advanced adult primary liver cancer; localized unresectable adult primary liver cancer; recurrent adult primary liver cancer; ...
  
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
  ClinicalTrials.gov Identifier: NCT00276861 - Active, not recruiting
  Colorectal Cancer
  
• A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
  ClinicalTrials.gov Identifier: NCT00506207 - Active, not recruiting
  Colorectal Neoplasm; Gastric Neoplasm; Secondary
  
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
  ClinicalTrials.gov Identifier: NCT00075452 - Active, not recruiting
  adenocarcinoma of the pancreas; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00058149 - Active, not recruiting
  stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
  
• Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
  ClinicalTrials.gov Identifier: NCT00314353 - Active, not recruiting
  Colorectal Neoplasms
  
• Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00072553 - Active, not recruiting
  Stage IV rectal cancer; stage IV colon cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; ...
  
• Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00062426 - Active, not recruiting
  adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; ...
  
• Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00016198 - Active, not recruiting
  recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
  
• Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
  ClinicalTrials.gov Identifier: NCT00035867 - Active, not recruiting
  Myelodysplastic Syndromes
  
• Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00098982 - Active, not recruiting
  stage III colon cancer; stage IV colon cancer; stage III rectal cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer
  
• Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00004203 - Active, not recruiting
  transitional cell carcinoma of the bladder; recurrent bladder cancer; stage IV bladder cancer; ...
  
• Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum
  ClinicalTrials.gov Identifier: NCT00077233 - Active, not recruiting
  adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; recurrent rectal cancer; stage IV colon cancer; ...
  
• Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
  ClinicalTrials.gov Identifier: NCT00093652 - Active, not recruiting
  Adenocarcinoma of the Esophagus; recurrent esophageal cancer; stage II esophageal cancer; stage III esophageal cancer; stage IV esophageal cancer; ...
  
• Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00040820 - Active, not recruiting
  recurrent colon cancer; adenocarcinoma of the rectum; stage III colon cancer; stage III rectal cancer; Stage IV rectal cancer; ...
  
• Oxaliplatin and Capecitabine With or Without Hepatic Arterial Infusion of Floxuridine in Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases From Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00268463 - Active, not recruiting
  Liver Metastases; Stage IV Colon Cancer; Stage IV Rectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
  
• FLOX in Combination with Cetuximab in First-Line Treatment of Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00145314 - Recruiting
  Metastatic Colorectal Cancer
  
• OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00081237 - Active, not recruiting
  recurrent colon cancer; stage III colon cancer; stage IV colon cancer; recurrent rectal cancer; stage III rectal cancer; Stage IV rectal cancer
  
• Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00217711 - Active, not recruiting
  Colorectal Cancer
  
• Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00227734 - Active, not recruiting
  Colorectal Cancer
  
• A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
  ClinicalTrials.gov Identifier: NCT00439179 - Active, not recruiting
  Metastatic Pancreatic Cancer
  
• A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
  ClinicalTrials.gov Identifier: NCT00439426 - Active, not recruiting
  Nasopharyngeal Cancer
  
• Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
  ClinicalTrials.gov Identifier: NCT00114231 - Recruiting
  adenocarcinoma of the rectum; stage I rectal cancer
  
• Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00215982 - Active, not recruiting
  Metastatic Colorectal Cancer
  
• A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
  ClinicalTrials.gov Identifier: NCT00353262 - Active, not recruiting
  Colorectal Cancer
  
• Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00416494 - Active, not recruiting
  Colorectal Cancer
  
• A Phase II Study of Oxaliplatin Capecitabine and Pre-Operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer
  ClinicalTrials.gov Identifier: NCT00220051 - Active, not recruiting
  Rectal Cancer
  
• Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00186277 - Active, not recruiting
  Bladder Cancer
  
• Docetaxel and Oxaliplatin in Gastric Cancer
  ClinicalTrials.gov Identifier: NCT00382720 - Recruiting
  Stomach Neoplasms
  
• Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00268411 - Active, not recruiting
  Pancreatic Cancer
  
• Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00345761 - Active, not recruiting
  Colorectal Cancer
  
• Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00004126 - Active, not recruiting
  stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Oxaliplatin and 5-FU Based Preoperative Chemoradiation
  ClinicalTrials.gov Identifier: NCT00278694 - Recruiting
  Rectal Cancer
  
• Etoposide, Oxaliplatin and Capecitabine in Advanced HCC
  ClinicalTrials.gov Identifier: NCT00351195 - Recruiting
  Hepatocellular Carcinoma
  
• Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
  ClinicalTrials.gov Identifier: NCT00075543 - Active, not recruiting
  recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
  
• Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
  ClinicalTrials.gov Identifier: NCT00548197 - Recruiting
  Intravitreal Bevacizumab Injection; Pars Plana Vitrectomy; Tractional Retinal Detachment; Diabetic Retinopathy
  
• Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
  ClinicalTrials.gov Identifier: NCT00259402 - Recruiting
  Esophageal Neoplasms
  
• Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer
  ClinicalTrials.gov Identifier: NCT00525005 - Recruiting
  Stomach Neoplasms
  
• Adverse Drug Reactions of Different Brands of Ceftazidime Injection
  ClinicalTrials.gov Identifier: NCT00173901 - Active, not recruiting
  Infection
  
• Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Advanced Small Bowel Adenocarcinoma (Cancer)
  ClinicalTrials.gov Identifier: NCT00081198 - Not yet recruiting
  small intestine adenocarcinoma
  
• Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00004187 - Active, not recruiting
  recurrent colon cancer; stage III colon cancer; stage III rectal cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer
  
• Oxaliplatin-Oesophageal Cancer
  ClinicalTrials.gov Identifier: NCT00160030 - Active, not recruiting
  Esophageal Neoplasms
  
• Phase II - Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
  ClinicalTrials.gov Identifier: NCT00321100 - Recruiting
  Colorectal Neoplasms
  
• Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV NSCLC
  ClinicalTrials.gov Identifier: NCT00453115 - Recruiting
  Lung Cancer
  
• Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil, Leucovorin and Avastin
  ClinicalTrials.gov Identifier: NCT00507585 - Recruiting
  Liver Cancer
  
• Topical Amethocaine Gel for Intramuscular Injection in Term Neonates
  ClinicalTrials.gov Identifier: NCT00267111 - Active, not recruiting
  Pain
  
• Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients with Biliary Tract and Gallbladder Cancer
  ClinicalTrials.gov Identifier: NCT00142480 - Recruiting
  Biliary tract adenocarcinoma; Gallbladder adenocarcinoma
  
• Capecitabine in Combination with Oxaliplatin (XELOX) vs. Fluorouracil/Leucovorin as Adjuvant Therapy for Patients who have Undergone Surgery for Colon Carcinoma
  ClinicalTrials.gov Identifier: NCT00069121 - Active, not recruiting
  Colorectal Cancer
  
• AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00415298 - Active, not recruiting
  Head and Neck Cancer
  
• Validation of Self-Reported Needle Sharing Among Injection Drug Users
  ClinicalTrials.gov Identifier: NCT00341081 - Active, not recruiting
  Viral Infection
  
• Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC
  ClinicalTrials.gov Identifier: NCT00510107 - Recruiting
  Stomach Neoplasm; Stage IV; Recurrent
  
• Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
  ClinicalTrials.gov Identifier: NCT00526110 - Recruiting
  Gastrointestinal Diseases
  
• Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00448552 - Active, not recruiting
  Head and Neck Cancer
  
• Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00005050 - Active, not recruiting
  recurrent colon cancer; stage III colon cancer; stage III rectal cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer